Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637799 | 1.00 | CHRM2 (0.65) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL3743487 | 0.84 | CHRM2 (0.69) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL1549648 | 0.84 | CHRM2 (0.69) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL5171242 | 0.84 | CHRM2 (0.69) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL3743481 | 0.82 | CHRM2 (0.71) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL13470758 | 0.78 | CHRM2 (0.67) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| (S)-Aceclidine SCHEMBL9146471 | 0.78 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL21063805 | 0.78 | CHRM2 (0.67) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL7399043 | 0.78 | CHRM2 (0.67) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL7824053 | 0.78 | CYP2D6 (0.62) | CHRM2CHRM1CYP2D6CHRNA7BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | ALMIRALL PRODESFARMA, SA (ES) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | NQO2, QPCT, QARS1 | CHRM2 344/4885CHRM1 327/4885CYP2D6 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.